159. Xeroderma pigmentosum
[
4 clinical trials,
8 drugs（DrugBank:
2 drugs),
2 target genes / 8 target pathways ]
Searched query = "Xeroderma pigmentosum"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2010-022968-13-ES | 22/03/2011 | 19 March 2012 | Estudio clínico de fase II, multicéntrico, abierto de trabectedina (Yondelis®) en pacientes con cáncer de mama avanzado, HER2 negativo, positivo para receptores hormonales, con sobreexpresión o subexpresión del gen xeroderma pigmentosum de clase G (XPG). | Estudio clínico de fase II, multicéntrico, abierto de trabectedina (Yondelis®) en pacientes con cáncer de mama avanzado, HER2 negativo, positivo para receptores hormonales, con sobreexpresión o subexpresión del gen xeroderma pigmentosum de clase G (XPG). | Cáncer de mama avanzado. MedDRA version: 13 Level: LLT Classification code 10006204 Term: Carcinoma de mama | Trade Name: YONDELIS 0,25 mg polvo para concentrado para solución para perfusión Pharmaceutical Form: Powder for solution for infusion INN or Proposed INN: TRABECTEDINA Other descriptive name: TRABECTEDINA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.25- Trade Name: YONDELIS 1 mg polvo para concentrado para solución para perfusión Pharmaceutical Form: INN or Proposed INN: TRABECTEDINA Other descriptive name: TRABECTEDINA Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- | PharmaMar S.A. Sociedad Unipersonal | Authorised | Female: yes Male: no | 100 | Spain | ||||
| 2 | EUCTR2010-022968-13-BE | 16/03/2011 | 21 August 2017 | Study of the medicinal product Trabectedin in Patients with Advanced Breast Carcinoma. | Multicenter, Open-Label, Phase II Study of Trabectedin (Yondelis®) in Patients with Hormonal Receptors Positive, HER2 Negative, Advanced Breast Carcinoma, Overexpressing or Underexpressing Xeroderma Pigmentosum G Gene (XPG) | Advanced Breast Carcinoma MedDRA version: 14.0 Level: LLT Classification code 10006204 Term: Breast carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04] | Trade Name: Yondelis 0.25 mg powder for concentrate for solution for infusion. Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: trabectedine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.25- Trade Name: Yondelis 1 mg powder for concentrate for solution for infusion. Pharmaceutical Form: Powder for concentrate for solution for infusion INN or Proposed INN: trabectedine Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1- | Pharma Mar, S.A. Sociedad Unipersonal | Not Recruiting | Female: yes Male: yes | 100 | Phase 2 | Belgium;Spain | |||
| 3 | NCT00002811 | July 1996 | 19 February 2015 | T4N5 Liposome Lotion Compared With Placebo Lotion for Preventing Actinic Keratoses in Patients With Xeroderma Pigmentosum | A RANDOMIZED, DOUBLE BLIND, MULTI-CENTER CLINICAL STUDY TO TEST THE SAFETY AND EFFICACY OF T4N5 LIPOSOME LOTION ON PATIENTS WITH XERODERMA PIGMENTOSUM IN THE PROTECTION AGAINST ACTINIC KERATOSES | Precancerous Condition | Drug: liposomal T4N5 lotion | Applied Genetics | Not recruiting | 2 Years | 60 Years | Both | 30 | Phase 3 | United States;Germany;United Kingdom | |
| 4 | NCT00025012 | June 1991 | 19 February 2015 | Isotretinoin in Preventing Skin Cancer | Use Of Isotretinion For Prevention Of Skin Cancer In Patients With Xeroderma Pigmentosum Or Nevoid Basal Cell Carcinoma Syndrome | Melanoma (Skin);Non-melanomatous Skin Cancer | Drug: isotretinoin | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Not recruiting | 2 Years | N/A | Both | N/A | United States |